Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.37 |
| ▸ | NPY4R | P50391 | 3/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.35 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998545 | 0.96 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20935053 | 0.96 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL17722946 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL17815311 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL22643670 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL21861811 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL21912925 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL19704788 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL23877006 | 0.94 | FAP (0.44) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL21897649 | 0.93 | FAP (0.44) | FAPNPY5RNPY1RNPY4RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | FAP 4182/4885NPY5R 723/4885NPY1R 745/4885 |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | FAP 3670/4885NPY5R 4345/4885NPY1R 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.